IMVT

Immunovant develops experimental drugs to treat autoimmune diseases, which are conditions where the body's immune system attacks its own tissues. The company is currently testing IMVT-1402, a type of antibody (a protein that fights disease) designed to treat diseases including rheumatoid arthritis, lupus, myasthenia gravis, and Graves' disease. The company was founded in 2018 and is based in Durham, North Carolina.